Teva’s Neupogen ‘Biosimilar’ Will Likely Take Half of Market by 2016: Analyst

Drug Industry Daily
A A
Teva has scored a victory on the road to biosimilar approvals with the FDA’s OK of its copycat version of Amgen’s Neupogen, a win that could halve Amgen’s U.S. market share by the end of 2016, analysts say.

To View This Article:

Login

Subscribe To Drug Industry Daily